Experience with Different Tumor Types
Over the last three years, Champions has engrafted over 900 individual patient tumors, and of these, approximately 70 percent grew and established a patient-derived xenograft (PDX) model. A drug that benefited the patient, either through stabilization or regression of disease, was identified from 90 percent of these PDX models (data updated July 2015).
Patients receiving treatment guided by Champions TumorGraft® testing have responded to their individualized treatments and seen a reduction in the size of their tumors, with durable remissions.
Tested Tumor Types
Tumors that have been treated successfully using Champions TumorGraft testing include cancers of the colon, pancreas, gastric, esophagus, lung and breast, as well as sarcomas and others.
Treatment Solutions Evaluated
Champions TumorGraft® PDX models can predict the likely success of many therapies, including single-agent and combination chemotherapy regimens, targeted biological drugs and antiangiogenics.
Real-World Results: Personalized Cancer Treatment by Champions TumorGraft PDX Models
Our experience and successes encompass a wide and distinct variance of tumor types and patient diagnostics. Chamipions TumorGraft technology represents a breakthrough, with an individual approach to personalized cancer treatment. Below, is an example of one of our success stories.
The Science in Action — Dean, 63, Metastatic Pancreatic Cancer
Dean underwent extensive abdominal surgery to resect a cancer of the pancreas, but the cancer recurred 12 months after surgery. Dean was treated with the most common treatment (i.e., standard of care), the anticancer drug gemcitabine, for four months until the cancer began to grow despite treatment.
What Champions Oncology found:
Based on Champions TumorGraft testing, one of the treatments tested was mitomycin C – which is rarely used to treat pancreatic cancer. This treatment showed a significant response in the PDX model.
Targeted Treatment Results
Based on personalized Champions TumorGraft findings, Dean received three cycles of mitomycin C. His blood tumor marker (used to measure the tumor in the blood) was previously 98,000, and based on Champions TumorGraft-directed treatments, was reduced to under 100. After 22 months of treatment, Dean was treated with two additional cycles of mitomycin C and three cycles of cisplatin.
Dean’s cancer remained in remission for over five years. The average survival of patients with metastatic pancreatic cancer is approximately six to eight months.
Individual outcomes may vary.